赞尼达单抗治疗HER2过表达晚期子宫内膜癌及癌肉瘤的2期试验(ZW25-IST-2)
这项单臂2期开放标签研究纳入16例既往治疗进展的HER2阳性子宫内膜癌/癌肉瘤患者,评估赞尼达单抗(ZW25)疗效与安全性。研究未达到主要终点,客观缓解率仅6.2%,24周临床获益率37.5%;8例存在瘤内HER2异质性或FISH未扩增,4例复测中3例HER2表达下降。作者认为复发后HER2靶向治疗前应考虑重新检测HER2。
要点
- 赞尼达单抗在复发HER2阳性子宫内膜癌/癌肉瘤中客观缓解率仅6.2%,未达主要疗效终点。
- 24周临床获益率为37.5%,仅1例达到部分缓解。
- 8例存在瘤内HER2异质性或FISH未扩增,复测中3/4例HER2表达下降。
核心结论
- 在复发性HER2阳性子宫内膜癌/癌肉瘤中观察到赞尼达单抗缓解率低,可能由HER2表达下调驱动。
- 作者建议在接受二线HER2靶向治疗前考虑重新检测HER2。
研究设计与样本
- 单臂2期开放标签研究,纳入16例既往≤2线治疗进展的HER2阳性子宫内膜癌/癌肉瘤患者。
- 主要终点为按实体瘤疗效评价标准1.1版评估的客观缓解率(完全或部分缓解)。
- 治疗前样本行HER2免疫组化与荧光原位杂交(FISH)检测,并评估瘤内HER2遗传异质性。
主要发现
- 研究未达到主要疗效终点,24周临床获益率为37.5%,仅1例达到部分缓解(客观缓解率6.2%)。
- 8例存在瘤内HER2异质性或FISH未显示HER2扩增。
- 4例复测治疗前样本中3例(75%)观察到HER2表达下降。
临床怎么用
- 作者建议在接受二线HER2靶向治疗前考虑重新检测HER2。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but HER2-directed therapy in the recurrent setting is limited. Zanidatamab (ZW25), a humanized, bispecific antibody that simultaneously binds the 2 distinct HER2 epitopes bound by trastuzumab and pertuzumab, has demonstrated safety and activity in HER2+ tumors. Here, we report the results of a phase 2, open-label study evaluating the efficacy and safety of zanidatamab in patients with HER2+ metastatic endometrial carcinoma/carcinosarcoma who received prior treatment. METHODS: We enrolled 16 patients with HER2+ endometrial carcinoma/carcinosarcoma after progression on ≤2 lines of therapy on a single-arm phase 2 study of zanidatamab. The primary endpoint was overall response rate (ORR; complete or partial response) by Response Evaluation Criteria in Solid Tumors version 1.1. HER2 immunohistochemistry and fluorescence in situ hybridization (FISH) were performed on pretreatment samples. Intratumor HER2 genetic heterogeneity was assessed. RESULTS: This study did not meet its primary efficacy endpoint. Although a clinical benefit rate of 37.5% was observed by 24 weeks, only 1 patient achieved a partial response (ORR, 6.2%). Eight patients had HER2 intratumor heterogeneity or lacked HER2 amplification by FISH. Decreased HER2 expression on repeat pretreatment samples was observed in 3 (75%) of 4 patients evaluated. CONCLUSIONS: We observed a low response rate to zanidatamab in recurrent HER2+ endometrial carcinoma/carcinosarcoma, which may be driven by downregulation of HER2 expression. Repeat HER2 testing should be considered prior to second-line HER2-directed therapy. CLINICALTRIALS: govidentifier: NCT04513665.
引用
- Lumish M, Chui MH, Zhou Q, et al. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2). Gynecol Oncol. 2024. PMID: 38262242. doi:10.1016/j.ygyno.2023.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。